Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescents with cystic fibrosis

Altabee, Rana, Carr, Siobhán B., Abbott, Janice, Cameron, Rory ORCID: https://orcid.org/0000-0002-7442-0935, Office, Daniel, Simmonds, Nicholas J., Whitty, Jennifer A. ORCID: https://orcid.org/0000-0002-5886-1933, Turner, David ORCID: https://orcid.org/0000-0002-1689-4147 and Barton, Garry (2024) Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescents with cystic fibrosis. Respiratory Medicine and Research, 86. ISSN 2590-0412

Microsoft Word (OpenXML) (Quality_Of_Life_in_CF_120623_final_draft_v.2.2) - Accepted Version Available under License Creative Commons Attribution. Download (112kB)

Abstract

Background: The EQ-5D is the recommended measure to capture health-related quality of life (HRQoL), recognised for use in health technology appraisal bodies. In order to assess whether it is appropriate to use the EQ-5D for making decisions about the cost-utility of treatments in cystic fibrosis (CF), this study assesses the performance of the EQ-5D-5L in adults and adolescents with CF.   Method: This was a cross-sectional observational survey study of patients with CF attending a single large CF centre. Participants were asked to complete a survey that included two HRQoL measures; the EQ-5D-5L and CF Quality of Life (CFQoL) questionnaires.   Results: Among 213 participants, the median EQ-5D-5L index score was 0.76 (IQR 0.66 – 0.84) and the visual analogue (EQ-VAS) was 70 (60 – 80). Both the EQ-5D index and EQ-VAS discriminated between disease severity based on lung function (p=0.01 and p<0.01, respectively) and pulmonary exacerbation (p=0.02 and p<0.01, respectively); however, EQ-VAS differentiated between more lung function severity groups compared to EQ-5D index. The EQ-5D-5L demonstrated convergent validity as its dimensions, index score, and EQ-VAS had significant correlations with most CFQoL domains. Though, EQ-VAS significantly predicted more domains of CFQoL (4 domains) compared to EQ-5D index (only 1 domain).   Conclusion: The generic EQ-5D-5L performed adequately in discriminating between CF disease severity, and its index score and EQ-VAS had moderate correlations with CFQoL. However, using a complementary condition-specific measure alongside the EQ-5D-5L can provide better insight of HRQoL in CF and benefit the process of cost-utility analysis.

Item Type:	Article
Additional Information:	Funding information: This project is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Program (Grant Reference Number PB-PG-1217–20,018). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. RA is funded by a PhD studentship from King Saud bin Abdulaziz University for Health Sciences (KSAU-HS). JW and RC involvement were also supported by the National Institute of Health Research (NIHR) Applied Research Collaboration East of England (ARC EoE) program. Views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Uncontrolled Keywords:	cystic fibrosis,quality of life,health-related quality of life,patient-reported outcomes,health-related quality of life,cystic fibrosis,patient-reported outcomes,quality of life,pulmonary and respiratory medicine ,/dk/atira/pure/subjectarea/asjc/2700/2740
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Centres > Norwich Institute for Healthy Aging Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Centres > Population Health Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	20 Aug 2024 13:30
Last Modified:	01 Nov 2024 04:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/96284
DOI:	10.1016/j.resmer.2024.101137

Downloads

Actions (login required)

View Item